Shionogi links with Quark in osteoarthritis deal:
This article was originally published in Clinica
US company Quark Biotech has linked in a research and licensing agreement with Shionogi of Japan to discover, identify, and determine the function of genes associated with osteoarthritis. Osaka-based Shionogi plans to develop and manufacture candidate diagnostic products for the disease using the information. It will have exclusive marketing rights in Japan and Asia to any products resulting from the deal. The company, whose main focus is pharmaceuticals, also expects to gain experience in discovery-related genomics and bioinformatics. The two companies will share co-marketing rights in the rest of the world. San Ramon, California-based Quark claims to have a comprehensive portfolio of genomic technologies and bioinformatics systems.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.